Unraveling Interaction of Rhenium-188 Microspheres with Primary Hepatic Cancer Cell: A Breakthrough Study
Cancer Biotherapy and Radiopharmaceuticals · 2024
DOI: 10.1089/cbr.2023.0146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Aarti Aggarwal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, PGIMER Chandigarh, Chandigarh, India. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Rhenium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Hepatocellular carcinoma is a prevalent contributor to global mortality rates. The main palliative treatments are trans-arterial chemoembolization and selective intra-arterial radionuclide therapy.
Methods
A novel freeze-dried nonradioactive microsphere kit formulation has been developed, and the behavior and therapeutic potential of 188 Re microspheres have been assessed. The microspheres were labeled with fluorescein isothiocyanate (FITC) and 188 ReO 4 − . The uptake of FITC microspheres by HepG2 cells was examined at various time intervals. The impact of 188 Re microspheres on cell viability and the mode of cell death were investigated with HepG2 cells using MTT and Annexin FITC-V/propidium iodide (PI) apoptosis assay.
Results
The labeling efficiency of microspheres was more than 99% with FITC and 188 ReO 4 − . The maximum uptake of FITC microspheres by HepG2 cells was achieved at 6 h. The exposure to 188 Re microspheres has shown a decrease in cellular viability from 77.81% ± 0.015% to 42.03% ± 0.148% at 192 h of incubation (∼11 half-lives). The cellular uptake of 188 Re microspheres was 0.255–0.901 MBq. These values were concordant with Annexin FITC-V/PI apoptosis assay. At 192 h, 53.28% ± 0.01% of cells entered the apoptotic phase after treatment with 188 Re microspheres, and only 39.34% ± 0.02% of cells remained viable. However, in the cells treated with 188 ReO 4 − alone, 74.86% ± 0.005% of cells were viable, and only 24.75% ± 0.577% of cells were in the early apoptotic phase at 192 h.
Conclusion
The data revealed that 188 Re microspheres treatment led to significant growth inhibition in HepG2 cells compared with 188 ReO 4 − .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, PGIMER Chandigarh, Chandigarh, India.
- Department of Pharmacology, PGIMER Chandigarh, Chandigarh, India.
- Department of Biochemistry, PGIMER Chandigarh, Chandigarh, India.
ORCID-Profile: Jaya Shukla
Zitieren
APA
Aggarwal, A., Kaur, G., Jassal, R. S., Medhi, B., Mittal, B. R., & Shukla, J. (2024). Unraveling Interaction of Rhenium-188 Microspheres with Primary Hepatic Cancer Cell: A Breakthrough Study. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2023.0146
Vancouver
Aggarwal A, Kaur G, Jassal RS, Medhi B, Mittal BR, Shukla J. Unraveling Interaction of Rhenium-188 Microspheres with Primary Hepatic Cancer Cell: A Breakthrough Study. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2023.0146
BibTeX
@article{Aggarwal2024,
author = {Aggarwal, Aarti and Kaur, Gurjeet and Jassal, Ravjit Singh and Medhi, Bikash and Mittal, Bhagwant Rai and Shukla, Jaya},
title = {Unraveling Interaction of Rhenium-188 Microspheres with Primary Hepatic Cancer Cell: A Breakthrough Study},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2024},
doi = {10.1089/cbr.2023.0146}
}
EUVIMED